6 completed, 2 terminated, 1 not yet recruiting. 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 6, Terminated 2, Not yet recruiting 1 |
Follow Achieve Life Sciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes Cytisinicline, Placebo, Behavioral Support - Vaping Cessation | Phase 3 | Not yet recruiting | Achieve Life Sciences | 800 | 2026-05-15 | 2026-02-06 |
| Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers Cytisinicline - Smoking Cessation, Vaping Cessation | Phase 3 | Completed | Achieve Life Sciences | 479 | 2024-05-28 | 2025-11-26 |
| A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers Cytisinicline, Placebo, Behavioral support - Smoking Cessation | Phase 3 | Completed | Achieve Life Sciences | 792 | 2022-01-20 | 2026-01-14 |
| A Study of Cytisinicline for Smoking Cessation in Adult Smokers Cytisinicline, Placebo, Behavioral support - Smoking Cessation | Phase 3 | Completed | Achieve Life Sciences | 810 | 2020-10-13 | 2026-01-15 |
| A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Custirsen, Docetaxel - Non-Small Cell Lung Cancer | Phase 3 | Completed | Achieve Life Sciences | 664 | 2012-10-24 | 2026-04-15 |
| Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer cabazitaxel, prednisone, custirsen sodium - Prostate Cancer | Phase 3 | Completed | Achieve Life Sciences | 630 | 2012-08-01 | 2016-10-12 |
| Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer Custirsen, Docetaxel, Prednisone - Prostate Cancer | Phase 3 | Completed | Achieve Life Sciences | 1022 | 2010-11-01 | 2016-10-14 |
| A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel - Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer | Phase 3 | Terminated | Achieve Life Sciences | 14 | 2010-03-01 | 2016-10-12 |
| Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer Taxol, TOCOSOL Paclitaxel - Breast Neoplasm | Phase 3 | Terminated | Achieve Life Sciences | 821 | 2005-09-01 | 2009-06-04 |
Smoking Cessation (3) · Prostatic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1)
OGX-011 (4) · cytisine (4) · Behavior Therapy (3) · Docetaxel (3) · Prednisone (3) · cabazitaxel (2) · Dexamethasone (1) · Paclitaxel (1) · Sodium Chloride (1)
United States (8) · Canada (3) · France (3) · Hungary (3) · Spain (3) · United Kingdom (3) · Australia (2) · Germany (2) · Israel (2) · Italy (2) · Russia (2) · South Korea (2) · Belgium (1) · Czechia (1) · Netherlands (1)
Julie Ball (2) · Celestia Higano, MD (1) · Daniel Cain, Vice-President Clinical Research (1) · Joachim Von Pawel, MD (1) · Johann de Bono, Professor (1) · Karim Fazazi, MD (1) · Karim Fizazi, M.D., Ph.D. (1) · Kim Chi, MD (1) · Nancy Rigotti, MD (1) · Sebastien Hotte, MD (1) · Sebastien J Hotte, M.D. (1) · Thomasz Beer, MD (1) · Tomasz M Beer, M.D. (1)
PMID 40962497, PMID 24722180, PMID 28283282, PMID 29033099, PMID 37432430, PMID 40257755